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Pharmacogenomics of Vincristine- 
Induced Peripheral Neuropathy Implicates 
Pharmacokinetic and Inherited Neuropathy 
Genes
Galen E.B. Wright1,2, Ursula Amstutz2,3,4, Britt I. Drögemöller2,5, Joanne Shih2, Shahrad R. Rassekh2,3, 
Michael R. Hayden1,2, Bruce C. Carleton2,3,†, Colin J.D. Ross2,5,† and The Canadian Pharmacogenomics 
Network for Drug Safety Consortiuma
Vincristine is an effective chemotherapeutic drug for various cancers, including acute lymphoblastic leukemia (ALL). 
Unfortunately, clinical utility is restricted by dose- limiting vincristine- induced peripheral neuropathies (VIPN). We 
sought to determine the association of VIPN with a recently identified risk variant, CEP72 rs924607, and drug 
absorption, distribution, metabolism, and excretion (ADME) gene variants in pediatric ALL. This was followed by a 
meta- analysis of pharmacogenomic data from over 500 patients. CEP72 rs924607 was significantly associated with 
VIPN (P = 0.02; odds ratio (OR) = 3.4). ADME analyses identified associations between VIPN and ABCC1 rs3784867 
(P = 5.34 × 10−5; OR = 4.9), and SLC5A7 rs1013940 (P = 9.00 × 10−4; OR= 8.6); genes involved in vincristine 
transport and inherited neuropathies, respectively. Meta- analysis identified an association with a variant related to 
TTPA (rs10504361: P = 6.85 × 10−4; OR = 2.0), a heritable neuropathy-related gene. This study provides essential 
corroboratory evidence for CEP72 rs924607 and highlights the importance of drug transporter and inherited 
neuropathy genes in VIPN.
Vincristine is an antineoplastic agent that is used to treat various 
cancers. This includes the most common pediatric form, acute 
lymphoblastic leukemia (ALL), a cancer that has survival rates 
that have increased to over 90% in certain world regions in recent 
decades.1,2 Vincristine- induced neurotoxicity is a common and se-
vere adverse drug reaction (ADR) that can occur in over 50% of 
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Dose-limiting VIPNs have been shown to have a genetic 
component. Pharmacogenomic studies have begun to identify 
genetic factors that can help explain these adverse reactions, but 
more research is required in this regard.
WHAT QUESTION DID THIS STUDY ADDRESS?
 To assess whether the CEP72 biomarker and drug ADME 
pharmacogenomic variants are associated with VIPN in pediat-
ric patients with ALL.
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 We confirmed the association of CEP72 rs924607 with 
VIPN, providing additional evidence for the potential clinical 
utility of this biomarker. Further, we showed that genetic 
variation within the vincristine drug transporter (ABCC1) was 
also associated with VIPN. Last, we uncovered the first evidence 
that genes that cause inherited neuropathies (SLC5A7 and 
TTPA) may contribute to VIPN susceptibility.
HOW MIGHT THIS CHANGE CLINICAL 
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
 These findings will help guide the development of predic-
tive markers and neuroprotective strategies for VIPN in order 
facilitate precision medicine and optimal care on an individual-
ized basis for oncology patients.
Study Highlights
†These authors jointly supervised this work.
aThe Canadian Pharmacogenomics Network for Drug Safety Consortium member details are given in the acknowledgements.
ARTICLE
CLINICAL PhARMACOLOgy & ThERAPEUTICs | VOLUME 105 NUMBER 2 | FEBRUARY 2019 403
vincristine- treated patients.3–5 This potentially life- threatening 
and debilitating toxicity includes vincristine- induced peripheral 
neuropathy (VIPN), which can cause loss of motor function, abnor-
mal sensation, and pain.6 This reaction severely affects the quality 
of life of patients, as well as influences the dosing and clinical utility 
of the drug.7 Genetic causes are thought to play an important role 
in this ADR because VIPN- susceptibility varies across ancestries8 
and the trait has been shown to be heritable in model organisms.9
Pharmacogenomics provide an attractive approach to mitigate 
VIPN – predictive testing would allow patients to be stratified 
according to risk before treatment, allowing for either increased 
monitoring or dose changes in at- risk patients. Furthermore, 
the identification of genetic risk factors may provide novel in-
sights into the mechanisms underlying variability in VIPN- 
susceptibility. Recently, a genome-wide association study (GWAS) 
in two cohorts reported that variation linked to the microtubule- 
organizing centrosomal protein, CEP72, significantly contrib-
utes to the risk of VIPN in pediatric ALL.10 This is in line with 
the mechanism of action of vincristine, which perturbs mitosis 
by interfering with microtubule formation.7,11 An initial replica-
tion study failed to detect a significant association between this 
CEP72 risk genotype and VIPN,12 which may have been driven 
by differences in the therapy stage during which VIPN was as-
sessed (i.e., continuation vs. induction).13 Subsequently, members 
of the research group involved in the discovery of the CEP72- 
VIPN association replicated this finding in a clinical trial of adult 
patients with ALL,14 but confirmation in an independent pediat-
ric cohort is still warranted.
We, therefore, assessed the relationship between VIPN and 
CEP72 genotype in a retrospective cohort of pediatric patients 
with ALL. This was followed by an exploratory analysis of phar-
macogenomic variants from absorption, distribution, metabolism, 
and excretion (ADME) genes and a meta- analysis of ADME ge-
netic variants that overlapped variants from the previous GWAS.10 
Studies such as these provide essential corroboratory clinical evi-
dence for previously identified drug safety biomarkers, while also 
identifying additional variants for future study.
RESULTS
A total of 167 cases (i.e., VIPN grade ≥ 2) and 57 controls (i.e., 
VIPN grade 0) met clinical and genomic quality control and 
were included in the discovery pharmacogenomic association 
studies, after excluding 29 patients with grade 1 VIPN and 12 
patients with only cranial or autonomic neurotoxicities (Figure S1, 
Table S1). This study design is classified as a nonmatched case- 
control association study, in which significantly different clinical 
and demographic factors between cases and controls were cor-
rected for during pharmacogenomic association analyses. The 
majority of VIPN cases were classified as grade 2 (n = 100), fol-
lowed by grade 3 (n = 66), and grade 4 (n = 1). The median days 
from first vincristine dose to VIPN were 57 (interquartile range: 
18–127 days). Patients were predominantly of European genetic 
ancestry (78%, Figure S2) and treatment protocol information 
is listed in Table S2. Table 1 depicts differences in clinical and 
demographic factors between VIPN cases and controls. Cases 
were more likely to be male and received vincristine for a longer 
duration compared to controls (median of 812 days vs. median of 
757 days). All controls, however, received vincristine for at least 
16 months, a period of time in which 94% of cases had developed 
VIPN (Figure S3), indicating sufficient follow- up time. The cu-
mulative vincristine dose was not significantly associated with 
case status, whereas duration of treatment was. This observation 
may have resulted from the fact that many VIPN cases had either 
vincristine doses held or reduced during treatment as a result of 
the experienced toxicities, which may explain the difference in 
therapy duration and the lack of association with cumulative dose. 
Cases were also more likely to have received nifedipine compared 
to controls. To help reduce the influence of potential confound-
ers on the genetic association analyses, all significantly associated 
demographic/clinical variables (i.e., sex, vincristine duration, and 
nifedipine use) were included as covariates in regression models 
along with genetic ancestry.
Table 1 Clinical and demographic characteristics of the 
CPNDS pediatric patients with ALL
Patient 
characteristics
Cases 
(n = 167) 
VIPN grade ≥ 2
Controls 
(n = 57) 
VIPN grade = 0 P value
Age, years (median 
(IQR))
4.8 (3.3–9.0) 5.4 (3.3–9.0) 0.63
Sex (male n, (%)) 101 (60.4%)  23 (40.4%) 0.009
Vincristine 
duration, days 
(median (IQR))
812 
(759–1137)
 757 
(745–825)
0.0004
Vincristine 
cumulative dose, 
mg/m2 (median 
(IQR))
61.4 
(48.0–72.0)
66.0 
(51.0–74.8)
0.17
Vincristine doses, 
number (median 
(IQR))
39 (32–45) 38 (37–39) 0.47
Concomitant medication (n, (%))
Strong cy-
tochrome P450 
3A inhibitorsa
59 (35.3%) 17 (29.8%) 0.52
Antifungal azoles 54 (32.3%) 14 (24.6%) 0.32
Nifedipine 22 (13.2%) 1 (1.8%) 0.01
Genetic ancestry (median (IQR))
PC 1 (African 
from 
non- African)
0.011 
[0.010–0.012]
0.010 
[0.008–0.012]
0.03
PC 2 (European 
from Asian)
0.020 
[0.017–0.022]
0.019 
[0.011–0.021]
0.17
PC 3 (South 
Asian from 
non- South 
Asian)
0.008 
[0.005–0.012]
0.006 
[0.002–0.010]
0.02
PC 4 (Amerindian 
from 
non-Amerindian)
0.010 
[0.006–0.013]
0.010 
[0.005–0.012]
0.37
ALL, acute lymphoblastic leukemia; CPNDS, Canadian Pharmacogenomics 
Network for Drug Safety; IQR, interquartile range; PC, principal component.The 
Wilcoxon rank- sum test or Fisher’s exact test where appropriate. P < 0.05 
regarded as significant and is displayed in bold in the table.
aClassified as inhibitors according to the Flockhart Table35
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The CEP72  rs924607 TT genotype was significantly associ-
ated with VIPN in the Canadian Pharmacogenomics Network 
for Drug Safety (CPNDS) cohort (one- sided P = 0.02; odds ratio 
(OR) = 3.43; 90% confidence interval (CI) = 1.15–10.3). The 
TT risk genotype frequencies for CEP72 rs924607 were 16.0% in 
VIPN cases and 5.4% in controls (Figure 1a, Table S3), display-
ing a specificity of 0.95 (95% CI = 0.85–0.99) and sensitivity of 
0.16 (95% CI = 0.11–0.22). The association between the CEP72 
rs924607-TT genotype and VIPN was further confirmed in a 
meta- analysis of the CPNDS results and published- CEP72-VIPN 
studies (Figure 1b; n studies = 4; P = 8.02 × 10−11; OR = 2.77; 
95% CI = 2.04–3.76; no heterogeneity: I2 = 0.0%).
Subsequent analysis of 4,522 ADME variants meeting the in-
clusion criteria for association testing revealed that no other pre-
viously identified variant was significantly associated with VIPN 
(i.e., P < 0.05; Table S4). Further, no variants assessed within 
the vincristine metabolism- related gene cluster (i.e., CYP3A5- 
CYP3A7- CYP3A4) displayed P < 0.05. An intronic ABCC1 
polymorphism (Table S5) was the top ADME variant with the 
strongest evidence of association (rs3784867 P = 5.34 × 10−5; 
OR = 4.91; 95% CI = 1.99–12.10; specificity = 0.88; sensitivity 
= 0.36; Table S6). The frequency of rs3784867 genotypes cor-
related with VIPN grade upon the inclusion of grade 1 patients 
(Figure 2a; P = 7.12 × 10−4). We assessed ABCC1 rs3784867 for 
replication in the previously published VIPN- GWAS summary 
statistics,10 and, although the risk allele was more frequent in cases 
in both the St Jude Total XIIIB and COG AALL0433, only sug-
gestive evidence for replication in the combined XIIIB- COG co-
horts was observed (one- sided P = 0.08). Interestingly, the third 
most significant finding from the ADME analyses was a missense 
variant in SLC5A7 (rs1013940 P = 9.00 × 10−4; OR = 8.60; 95% 
CI = 1.68–44.15; specificity = 0.96; sensitivity = 0.18; Table S7), 
a gene that encodes a choline transporter, where mutations are 
known to cause a form of hereditary motor neuropathy.15 Of 
note, all homozygous risk variant carriers presented with the most 
severe VIPN grade (Figure 2b). This variant is also an SLC5A7 
expression quantitative trait locus (eQTL and Genotype- Tissue 
Expression (GTEx) multitissue P = 3.62 × 10−7).16 Unfortunately, 
Figure 1 CEP72 is significantly associated with vincristine- induced peripheral neuropathies (VIPN) in pediatric patients with acute 
lymphoblastic leukemia. (a) Recessive genotype frequencies for CEP72 rs924607 differed significantly between VIPN cases and controls 
(P = 0.02). The TT risk genotype occurred in 16.0% of cases (VIPN grade ≥2) and 5.4% of controls (VIPN grade 0). (b) Meta- analysis of the 
association of CEP72 rs924607 and VIPN confirms the role of this variant with vincristine- related adverse effects. The gray summary diamond 
indicates meta- analysis results including all studies, whereas the blue summary diamond shows the results for studies where VIPN was 
assessed throughout continuation therapy (i.e., excluding the Gutierrez- Camino et al.12 study). Genotype 95% confidence intervals (CIs) are 
represented for consistency across all studies, as opposed to the 90% CI that was used to determine CEP72 rs924607 replication evidence 
for the Canadian Pharmacogenomics Network for Drug Safety cohort in the current study.10,13,14
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no data were available for this variant or those in linkage disequi-
librium in the GWAS summary statistics, so we were unable to as-
sess the SLC5A7 variant for replication or in the meta- analysis.
We performed annotation of the ABCC1 rs3784867 variant to 
delineate its potential functional role. No variants in strong LD 
(i.e., r2 > 0.8 and no missense variants with D′ > 0.8) with the 
marker were identified in the 1,000 Genomes Project. Annotation 
of rs3784867 with DNAse and histone ChIP- Seq data indicated 
the presence of enhancer and histone marks in five tissues/cell types 
(i.e., embryonic stem cells, induced pluripotent stem cells, hemato-
poietic stem cells, smooth muscle, and the pancreas). Additionally, 
rs3784867 was predicted to alter homeobox transcription factor 
motifs (Figure S4).
The most significant association detected in the VIPN- ADME- 
GWAS meta- analysis (Table S8) of 379 variants was rs10504361 
(P = 6.85 × 10−4; OR = 1.98; 95% CI = 1.34–2.94; Figure 3). 
This variant is a GTEx- eQTL16 for the TTPA and GGH genes. 
Because TTPA mutations are known to cause ataxia with isolated 
vitamin E deficiency, a neurologic condition associated with neu-
ropathies,17 we assessed differences in predicted gene expression of 
TTPA in the tibial nerve with S- PrediXcan, which collapses eQTL 
data by gene, in the GWAS- array genotyped cohorts. These analy-
ses revealed positive gene- level Z- scores in both cohorts, indicating 
that VIPN cases were predicted to have increased expression com-
pared to controls (P = 6.1 × 10−5).
DISCUSSION
Pediatric oncology has seen a dramatic improvement in the prog-
nosis for patients over recent decades, yet ADRs from these drugs 
have become an increasing concern. In this study, we independently 
Figure 2 Top absorption, distribution, metabolism, and excretion (ADME)- vincristine- induced peripheral neuropathies (VIPN) variant genotypes 
stratified by severity of the adverse event. (a) ABCC1 rs3784867 was the most significantly associated pharmacogenomic variant in the 
VIPN- ADME analyses (P = 5.34 × 10−5; odds ratio (OR) = 4.9). Genotype frequency was also correlated with severity of the adverse event 
(P = 7.12 × 10−4). (b) SLC5A7 rs1013940 is a missense variant in a peripheral neuropathy gene that was among the most significantly 
associated ADME variants (P = 9.00 × 10−4; OR = 8.6). The variant was also moderately associated with VIPN grade severity (P = 0.01), 
with all homozygous carriers of the risk allele presenting with severe VIPN (i.e., grade 3 and 4). Because only one case of grade 4 VIPN was 
observed in this cohort, this patient was combined with the grade 3 group.
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confirmed a role of CEP72 rs924607 in VIPN susceptibility for 
the first time in a retrospective cohort of pediatric patients. This 
finding validates the importance of this pharmacogenomic vari-
ant for the prediction of a serious ADR caused by an essential che-
motherapeutic agent. Our exploratory pharmacogenomic analyses 
also brought to light the potential VIPN- related importance of 
the transporter, ABCC1, and highlighted genes associated with 
inherited neuropathy conditions, such as SLC5A7 and TTPA.
Confirmation of CEP72 as a pharmacogenomic risk factor 
for VIPN
CEP72 rs924607 is a promising VIPN biomarker given its po-
tential role in the mechanism of action of this antimitotic agent. 
However, prior to the current study, all evidence supporting this 
finding was obtained from a single research group, although for 
the most recent replication study,14 these investigators collabo-
rated on the study by performing genotyping of CEP72 rs924607 
while blinded to VIPN phenotype. Of note, this the only other ex-
ternal study refuting the role of this variant in VIPN. Our positive 
results, supported by a meta- analysis of published VIPN- CEP72 
studies,10,12,14 provide the first external validation of this finding 
in pediatric patients. In particular, the replication of CEP72 in 
a diverse pediatric ALL cohort confirms the generalizability of 
this pharmacogenomic marker. Our data also improve the preci-
sion and accuracy of estimates regarding the effect of this variant 
(meta- analysis: P = 8.02 × 10−11; OR = 2.77; 95% CI = 2.04–
3.76) in studies assessing VIPN from vincristine continuation 
therapies. Concurrently, these results corroborate the validity of 
our grading scheme that retrospectively assessed VIPN based on 
medical records of patients recruited via active surveillance.
The failure of the first rs924607- VIPN replication attempt12 
brings to light important phenotypic considerations for pharma-
cogenomic studies. Unlike the discovery study, which included 
monitoring during induction and continuation phases of vin-
cristine therapy, Gutierrez- Camino et al.12 assessed VIPN solely 
during the 4- week induction phase of vincristine therapy. Of note, 
the majority (63%) of the VIPN cases in our cohort developed tox-
icity after this 4- week time frame (Figure S3). Our meta- analysis 
was highly significant when excluding this study12 assessing VIPN 
only during induction therapy from analysis with no evidence for 
heterogeneity between studies. It has further been suggested that 
CEP72 rs924607 may be primarily relevant to patients receiving 
vincristine doses of <2 mg/m2 because higher doses of vincris-
tine may overcome the protective influence of the ancestral geno-
types.13 Indeed, when excluding the CPNDS patients that received 
vincristine doses ≥ 2 mg/m2 (i.e., 34.3% of the cohort), the risk 
genotype was carried exclusively in cases (i.e., 16.1% of 112 cases; 
Fisher’s exact P = 0.007). These findings emphasize the impor-
tance of carefully matching drug- induced phenotypes in pharma-
cogenomic replication studies.18
Exploratory analyses of ADME genetic variation
Because numerous pharmacogenes belong to ADME- related 
pathways,19 we conducted an exploratory association analysis of 
Figure 3 Association of TTPA- related variation and gene expression with vincristine- induced peripheral neuropathy (VIPN). (a) Meta- analysis 
of overlapping absorption, distribution, metabolism, and excretion (ADME)- genomewide association study (GWAS) variants in the Canadian 
Pharmacogenomics Network for Drug Safety (CPNDS)/St Jude Total XIIIB/COG AALL0433 cohorts identified rs10504361 as the most 
significantly associated variant. (b) This variant has been shown to be associated with differential expression of the TTPA gene in the tibial 
nerve in GTEx. (c) Imputing expression of TTPA using genome wide array data revealed that VIPN cases were predicted to have higher levels of 
TTPA expression compared to controls as reflected by gene- level S- PrediXcan Z- scores (i.e., positive scores indicate increased expression is 
associated with increased risk for VIPN). CI, confidence interval; OR, odds ratio.
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ADME variants with regards to VIPN using a custom genotyp-
ing panel that extensively captures variation within these regions. 
Initial pharmacogenomic studies investigating VIPN hypothe-
sized that CYP3A genetic variation may be relevant for this ADR 
because vincristine is chiefly metabolized by these enzymes.8 Our 
results, however, indicate that pharmacogenomic variation in 
CYP3A genes did not contribute significantly toward this pheno-
type in our patient cohort.
Our analyses revealed that the ADME variant with the 
strongest evidence for an association with VIPN, rs3784867 
(P = 5.34 × 10−5; OR = 4.91; 95% CI = 1.99–12.10), occurs in 
the intron of ABCC1. This gene encodes multidrug resistance 
protein 1, a protein, which is involved in both transport of, and 
resistance to, vincristine.20,21 ABCC1 has also been implicated 
in anthracycline- related and methotrexate- related pharmacog-
enomic phenotypes.22 Rs3784867 is predicted to alter binding 
sites for homeobox transcription factors (Figure S4), which are 
involved in hematopoiesis and are dysregulated in leukemia,23 
indicating that rs3784867 could affect the expression of ABCC1. 
Notably, previous pharmacogenomic studies have detected associ-
ations with ABCC1 and the paralogous transporter ABCC2 and 
VIPN- risk,24,25 although we did not replicate associations of the 
variants that were implicated in these studies. As discussed previ-
ously, heterogeneity in VIPN assessment may contribute toward 
the lack of transferability of pharmacogenomic markers between 
studies and because our study used an intervention- based VIPN 
grading scheme, this may have contributed toward these discrep-
ant results. The correlation between rs3784867 and ADR severity 
adds support for this variant’s role in VIPN risk. However, because 
only suggestive evidence for replication was observed in the GWAS 
summary statistics for rs3784867, it is, important to further inves-
tigate this variant in additional VIPN cohorts.
Overlap between the genomics of VIPN and inherited 
neuropathy conditions
It has been suggested that a continuum exists between the genetic 
etiology of Mendelian disorders and drug- induced traits that pres-
ent with similar clinical phenotypes.26 This is in line with what 
has been observed for GWAS of chemotherapy- induced periph-
eral neuropathies from paclitaxel (FGD4 gene)27 and docetaxel 
(VAC14 gene),28 whereas both genes have also been implicated 
in inherited neuropathy conditions. Phenotype overlaps are fur-
ther substantiated by the fact that vincristine is contraindicated 
in patients with hereditary neuropathies (e.g., Charcot- Marie- 
Tooth disease), because VIPN can be particularly severe in these 
patients.29 Our VIPN- ADME- GWAS meta- analysis identified 
a variant (rs10504361) that is associated with the expression 
of TTPA in the peripheral nervous system. This protein influ-
ences bioavailability of alpha- tocopherol, a form of vitamin E. 
Deleterious TTPA mutations cause the recessive neurodegenera-
tive condition ataxia with isolated vitamin E deficiency, which is 
associated with peripheral neuropathy.30 In silico gene expression 
analysis indicated that cases were predicted to have increased lev-
els of TTPA in the tibial nerve when compared to controls. This 
finding warrants further research to delineate the potential mech-
anism of action of the variant in the context of VIPN. Sensory 
conduction in the tibial nerve has been shown to be impaired in 
vincristine treated patients with ALL31 and it has motor functions 
through innervating the muscles of the leg, including the tibialis 
posterior muscle, which is involved in plantar flexion.32 This in-
dicates that the tibial nerve may be an appropriate model to study 
gene expression in VIPN. Finally, our third most highly associated 
VIPN- ADME gene was SLC5A7, a choline transporter that is im-
plicated in distal hereditary motor neuropathy type 7A 15 and con-
genital myasthenic syndromes, which are associated with muscle 
weakness.33 Given that the association with VIPN was observed 
for a missense SLC5A7 variant (rs1013940) with a large effect 
size (OR > 8), and the similarity of the ADR and inherited phe-
notypes related to this gene, this candidate variant also warrants 
further investigation.
Context of current VIPN pharmacogenomic findings
With the availability of high throughput genotyping platforms, 
pharmacogenomic studies are beginning to uncover novel biology 
that contributes toward ADRs in a clinically relevant manner.19 
Although the current investigation provides valuable findings, 
there are caveats. Despite the fact that the sample size of the cur-
rent study is relatively large for a pharmacogenomic study, includ-
ing more patients in future cohorts would be beneficial. This is 
reflected by the fact that our exploratory analysis of ADME vari-
ants yielded no associations reaching statistical significance after 
stringent Bonferroni multiple testing correction. Additional con-
firmatory evidence should also be pursued in the future through 
functional experiments for the novel candidate genes identified 
in the ADME/GWAS analyses. Nonetheless, given the known 
involvement of the highlighted genes in vincristine pharmacoki-
netics and inherited neuropathy conditions, this study provides 
interesting avenues for future research. The retrospective nature 
of this study is also a potential limitation, because milder forms 
of VIPN may be poorly captured in standard medical records. 
We took great care in developing a slightly augmented Common 
Terminology Criteria for Adverse Events (CTCAE) grading 
scheme that can be applied in this context. Indeed, our results 
support the appropriateness of this grading scheme through the: 
(i) replication of the VIPN CEP72 GWAS variant with a similar 
effect size as previously reported; (ii) identification of candidate 
genes that have a clear biological mechanism pertaining to the 
ADR; and (iii) the correlation of the genotype frequencies of top 
candidate variants with VIPN severity.
Conclusions and future directions
VIPNs are important clinical concerns, especially given the in-
creased survival rates of pediatric patients with cancer and po-
tential long- term effects of this ADR. The confirmatory results 
obtained in the current study highlight the CEP72 rs924607 risk 
marker for further evaluation of its clinical utility in the context 
of potential pharmacogenomic risk predictions and preventive in-
terventions. Specifically, predicting in whom debilitating VIPN 
is likely to occur would allow clinicians to discuss other therapeu-
tic options, additional physiotherapy interventions, and, impor-
tantly, inform patients and parents in advance what toxicity may 
occur, further enhancing the family’s role in cancer management.
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Given the current level of evidence for the CEP72 risk gen-
otype, increased clinical monitoring and earlier initiation of 
physiotherapy interventions for VIPN in rs924607 TT patients 
could potentially be beneficial. Oncologists may also consider 
ALL treatment protocols with lower doses of vincristine and/or 
shorter vincristine treatment durations in high- risk genotypes. It 
is important to note that alternative protocols should fall within 
current standards of care and display similar efficacy and survival 
outcomes. The results of an ongoing clinical trial investigating the 
influence of vincristine dose and duration reductions in CEP72 
rs924607 TT patients (ClinicalTrials.gov: NCT03117751) will 
also be highly informative in determining whether pharmacog-
enomic genotyping can minimize VIPN risk while maintaining 
treatment efficacy.
Additional VIPN pharmacogenomic markers, if confirmed 
through future replication, may further improve VIPN risk strat-
ification. Finally, it will also be beneficial for future studies to use 
high- throughput sequencing approaches to delineate extreme cases 
of VIPN in future studies, given the importance of rare variation 
for pharmacogenomic traits.19 In particular, resequencing studies 
would enable the investigation of rare variants in candidate genes 
for VIPN, such as the ones identified in this study. Comprehensive 
risk assessments that take different clinical, demographic, and 
pharmacogenomic factors into account may, therefore, ultimately 
lead to safer and more effective use of vincristine- based chemother-
apy in children.
METHODS
Patients and clinical assessment
Pediatric patients with ALL (age at diagnosis ≤18  years) receiving 
treatment protocols, including vincristine, were recruited from seven 
pediatric hospitals across Canada (Calgary, London, Ottawa, Montréal, 
Toronto, Vancouver, and Winnipeg). Written informed consent and/or 
assent was obtained from all participants or their parents/legal guardians. 
The study was approved by ethics committees at participating universities 
and hospitals. Relevant clinical and demographic data were collected 
using the CPNDS active surveillance methodology.34 This included 
capturing information for relevant concomitant medications (e.g., CYP3A 
inhibitors, because these enzymes represent the major metabolic path of 
vincristine).7,35
Patients were assessed for vincristine- related neurotoxicities using 
a refined National Cancer Institute (NCI) CTCAE version 4.0 
Grading System (Table S1). Specifically, to facilitate grading of the 
retrospective clinical data and standardize grading across multiple sites, 
this system included definitions of neurotoxicity- related clinically based 
interventions, such as pharmacotherapy, rehabilitative therapy, and 
vincristine dose reductions, to complement the relatively broad definitions 
(e.g., “noninvasive intervention” or “limiting activities of daily living”) 
used in the CTCAE. To be considered for grading, any intervention 
had to be used specifically for the treatment for vincristine- related 
neurotoxicities, and any symptom had to be attributed to vincristine- 
related neurotoxicities. We excluded patients with grade one (minor) 
VIPN from our initial pharmacogenomic nonmatched case- control 
association analyses (Figure S1, cases were defined as grade ≥2, whereas 
controls were defined as patients not developing neuropathy, referred to 
as  grade 0), because the need for a predictive biomarker is greater in those 
patients with neurotoxicity of sufficient severity to warrant a modification 
in clinical care (increased monitoring and drug therapy changes). In 
addition, patients presenting only with symptoms of cranial or central 
nervous system neurotoxicities without motor or sensory neurotoxicity 
were not included in the analysis.
Pharmacogenomic genotyping and quality control
Genomic DNA from participants was genotyped for CEP72 rs924607 
using a TaqMan assay (C___8292459_20; ThermoFisher, Waltham, 
MA) and for 7,907 ADME variants with a custom Infinium Panel 
(Illumina, San Diego, CA).36 ADME genotype clusters were extracted 
from GenomeStudio Software (Illumina) and underwent standard 
quality control procedures. Specifically, array data were assessed for 
variant (≥95%) and sample call rates (≥90%), and deviations from Hardy 
Weinberg equilibrium (Fisher’s exact P < 0.001 in controls).
Bioinformatic and statistical analyses
Statistical and bioinformatic analyses were performed using either R or 
SNP & Variation Suite (SVS) version 8.4 (Golden Helix, Bozeman, MT), 
unless otherwise stated. Genetic ancestry was determined via principal 
component analyses using pruned ADME genotypes (50- variant window, 
shifted by 5- variants after each assessment, pruning r2  >  0.5) and minor 
allele frequency <0.01 with EIGENSOFT version 5.0, incorporating the 
1,000 Genomes Project37 samples as a reference. The first four principal 
components, along with clinical factors that differed significantly (P < 0.05) 
between cases and controls were included in subsequent case- control 
association analyses to correct for possible population stratification and 
clinical confounders. Sensitivity and specificity of prioritized variants were 
calculated with epiR (https://cran.r-project.org/web/packages/epiR).
To investigate the CEP72 rs924607 VIPN risk genotype, we decided a 
priori to first test for an association between this marker and VIPN using 
a recessive model, as reported in the initial study. For this analysis, a one- 
sided P value  <  0.05 was considered statistically significant. A random- 
effects meta- analysis was performed on CEP72 rs924607, incorporating 
the results from this study along with published data, using the GWAMA 
software38; related plots were generated in the R package, forestplot 
(https://CRAN.R-project.org/package=forestplot).
These analyses were followed by exploratory association analyses of 
ADME variants passing quality control, and displaying minor allele 
frequency >0.05, using logistic regression and an additive genetic model. 
Due to the exploratory nature of this analysis, multiple testing corrections 
using a conservative Bonferroni threshold was not applied. Instead, variants 
with P  <  0.001 were prioritized. To provide corroboratory evidence for 
top VIPN- associated variants, ordinal regression of VIPN grade was also 
performed using the R package ordinal.
An Embase literature search (further details are provided in Table S4) 
was completed to identify previously identified VIPN- related variants and 
assess their association with the ADR in the CPNDS cohort. Further, 
VIPN- GWAS summary statistics were obtained for the two pediatric 
ALL cohorts from Diouf et  al.10 and a meta- analysis of nonambiguous 
overlapping ADME variants with evidence for association (P < 0.05) in at 
least one cohort was performed as specified above.
To examine predicted functional effects of variants prioritized from 
the association analyses, Ensembl Variant Effect Predictor,39 HaploReg 
version 4.1,40 GTEx,16 and the JASPAR Core Database41 were used to 
annotate variants. Differences in predicted gene expression profiles in 
the tibial nerve16 between GWAS- genotyped VIPN cases and controls 
were calculated using S- PrediXcan,42 where specified, with P values being 
combined using Fisher’s method in metap (https://cran.r-project.org/web/
packages/metap).
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Figure S1. CONSORT diagram of pediatric ALL patients included in the 
CPNDS VIPN study.
Figure S2. Principal component analysis of the CPNDS VIPN cohort 
(cases, n = 167; controls, n = 57; grade 1 VIPN, n = 29), including 
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the Phase 3 1,000 Genomes Project samples as a reference (AMR, 
Admixed American; AFR, African; EAS, East Asian; EUR, European; 
SAS, South Asian).
Figure S3. Cumulative percentage of vincristine- induced peripheral 
neuropathy cases over time, indicating that 94% of cases developed 
in the first 16 months after initiating vincristine therapy (blue dashed 
line).
Figure S4. Human transcription factor binding site analysis of the 
ABCC1 rs3784867 variant (C>T).
Table S1. Refined CTCAE vincristine- induced neurotoxicity grading 
scale that specifies clinical interventions related to neurotoxicity.
Table S2. Summary of the treatment protocols for the CPNDS pediat-
ric ALL cohort included in the pharmacogenomic association analyses.
Table S3. CEP72 rs924607 genotype counts in pediatric patients with 
ALL stratified by VIPN status.
Table S4. Literature search strategy for identification of previously 
identified VIPN pharmacogenomic variants and assessment of these 
variants in the CPNDS ALL cohort.
Table S5. Top ADME variants associated with VIPN (P < 0.001) in the 
pediatric CPNDS ALL cohort.
Table S6. ABCC1 rs3784867 genotype counts in pediatric patients 
with ALL stratified by VIPN status.
Table S7. SLC5A7 rs1013940 genotype counts in pediatric patients 
with ALL stratified by VIPN status.
Table S8. Most significant associations from the VIPN- ADME- GWAS 
meta- analysis of the St Jude Total XIIIB, COG AALL0433, and CPNDS 
cohorts.
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